AAAAAA

   
Results: 1-24 |
Results: 24
Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder, BEST P R C, 14(2), 2001, pp. 299-319
Utility of the PFA-100 (R) for assessing bleeding disorders and monitoringtherapy: a review of analytical variables, benefits and limitations
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Utility of the PFA-100 (R) for assessing bleeding disorders and monitoringtherapy: a review of analytical variables, benefits and limitations, HAEMOPHILIA, 7(2), 2001, pp. 170-179
Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 (R) and vWF : CBA as combined diagnostic strategies
Authors: Favaloro, EJ Kershaw, G Bukuya, M Hertzberg, M Koutts, J
Citation: Ej. Favaloro et al., Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 (R) and vWF : CBA as combined diagnostic strategies, HAEMOPHILIA, 7(2), 2001, pp. 180-189
Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor
Authors: Favaloro, EJ Aboud, M Arthur, C
Citation: Ej. Favaloro et al., Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor, AM J HEMAT, 66(1), 2001, pp. 53-56
Human endothelial cells maintain anti-aggregatory activity for platelets during apoptosis
Authors: Xu, W Favaloro, EJ Medbury, H Zoellner, H
Citation: W. Xu et al., Human endothelial cells maintain anti-aggregatory activity for platelets during apoptosis, THROMB HAEM, 85(5), 2001, pp. 915-923
Detection of von Willebrand disorder and identification of qualitative vonWillebrand factor defects - Direct comparison of commercial ELISA-based von Willebrand factor activity options
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Detection of von Willebrand disorder and identification of qualitative vonWillebrand factor defects - Direct comparison of commercial ELISA-based von Willebrand factor activity options, AM J CLIN P, 114(4), 2000, pp. 608-618
Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey
Authors: Favaloro, EJ Thom, J Baker, R
Citation: Ej. Favaloro et al., Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey, BL COAG FIB, 11(8), 2000, pp. 729-737
Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations
Authors: Facey, DA Favaloro, EJ Maxwell, E Baker, R Hertzberg, MS
Citation: Da. Facey et al., Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations, AM J HEMAT, 63(4), 2000, pp. 197-199
Discrimination of von Willebrands disease (VWD) subtypes: Direct comparison of von Willebrand factor : collagen binding assay (VWF : CBA) with monoclonal antibody (MAB) based VWF-capture systems
Authors: Favaloro, EJ Henniker, A Facey, D Hertzberg, M
Citation: Ej. Favaloro et al., Discrimination of von Willebrands disease (VWD) subtypes: Direct comparison of von Willebrand factor : collagen binding assay (VWF : CBA) with monoclonal antibody (MAB) based VWF-capture systems, THROMB HAEM, 84(4), 2000, pp. 541-547
Collagen binding assay for von Willebrand factor (VWF : CBA): Detection ofvon Willebrands Disease (VWD), and discrimination of VWD subtypes, dependson collagen source
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Collagen binding assay for von Willebrand factor (VWF : CBA): Detection ofvon Willebrands Disease (VWD), and discrimination of VWD subtypes, dependson collagen source, THROMB HAEM, 83(1), 2000, pp. 127-135
Sulfatide-binding assay for von Willebrand factor: Detection of von Willebrand's disease without discrimination of vWD subtypes
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Sulfatide-binding assay for von Willebrand factor: Detection of von Willebrand's disease without discrimination of vWD subtypes, THROMB RES, 98(2), 2000, pp. 213-219
Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation
Authors: De Luca, M Facey, DA Favaloro, EJ Hertzberg, MS Whisstock, JC McNally, T Andrews, RK Berndt, MC
Citation: M. De Luca et al., Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation, BLOOD, 95(1), 2000, pp. 164-172
Laboratory testing, diagnosis, and management of von Willebrand disease - Current practice in Australasia
Authors: Favaloro, EJ Smith, J Petinos, P Collecutt, M Street, A Hertzberg, M
Citation: Ej. Favaloro et al., Laboratory testing, diagnosis, and management of von Willebrand disease - Current practice in Australasia, AM J CLIN P, 112(5), 1999, pp. 712-719
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT-based assays
Authors: Favaloro, EJ Mirochnik, O McDonald, D
Citation: Ej. Favaloro et al., Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT-based assays, BR J BIOMED, 56(1), 1999, pp. 23-33
Use of a novel platelet function analyzer (PFA-100 (TM)) with high sensitivity to disturbances in von willebrand factor to screen for von Willebrand's disease and other disorders
Authors: Favaloro, EJ Facey, D Henniker, A
Citation: Ej. Favaloro et al., Use of a novel platelet function analyzer (PFA-100 (TM)) with high sensitivity to disturbances in von willebrand factor to screen for von Willebrand's disease and other disorders, AM J HEMAT, 62(3), 1999, pp. 165-174
Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A
Authors: Hertzberg, MS Underwood, T Favaloro, EJ
Citation: Ms. Hertzberg et al., Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A, AM J HEMAT, 62(3), 1999, pp. 199-200
Type 2B von Willebrand's disease and angiodysplasia
Authors: Hertzberg, MS Facey, DA Favaloro, EJ Koutts, J
Citation: Ms. Hertzberg et al., Type 2B von Willebrand's disease and angiodysplasia, THROMB HAEM, 82(5), 1999, pp. 1557-1558
Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey
Authors: Favaloro, EJ Smith, J Petinos, P Hertzberg, M Koutts, J
Citation: Ej. Favaloro et al., Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey, THROMB HAEM, 82(4), 1999, pp. 1276-1282
A novel Factor V null mutation at Arg 506 causes a false positive Factor VLeiden result
Authors: Mirochnik, O Halim-Kertanegara, N Henniker, AJ Favaloro, EJ Tiley, CR Hertzberg, MS McDonald, DA
Citation: O. Mirochnik et al., A novel Factor V null mutation at Arg 506 causes a false positive Factor VLeiden result, THROMB HAEM, 82(3), 1999, pp. 1198-1199
Laboratory assessment as a critical component of the appropriate diagnosisand sub-classification of von Willebrand's disease
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Laboratory assessment as a critical component of the appropriate diagnosisand sub-classification of von Willebrand's disease, BLOOD REV, 13(4), 1999, pp. 185-204
Clinical utility of anticardiolipin antibody assays: High inter-laboratoryvariation and limited consensus by participants of external quality assurance programs signals a cautious approach
Authors: Favaloro, EJ Silvestrini, R Mohammed, A
Citation: Ej. Favaloro et al., Clinical utility of anticardiolipin antibody assays: High inter-laboratoryvariation and limited consensus by participants of external quality assurance programs signals a cautious approach, PATHOLOGY, 31(2), 1999, pp. 142-147
Comparison of the effects of two low fat diets with different alpha-linolenic : linoleic acid ratios on coagulation and fibrinolysis
Authors: Allman-Farinelli, MA Hall, D Kingham, K Pang, D Petocz, P Favaloro, EJ
Citation: Ma. Allman-farinelli et al., Comparison of the effects of two low fat diets with different alpha-linolenic : linoleic acid ratios on coagulation and fibrinolysis, ATHEROSCLER, 142(1), 1999, pp. 159-168
Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease
Authors: Facey, DA Favaloro, EJ Koutts, J Berndt, MC Hertzberg, MS
Citation: Da. Facey et al., Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease, BR J HAEM, 105(2), 1999, pp. 538-541
Medical research in New South Wales 1993-1996 assessed by Medline publication capture
Authors: Favaloro, EJ
Citation: Ej. Favaloro, Medical research in New South Wales 1993-1996 assessed by Medline publication capture, MED J AUST, 169(11-12), 1998, pp. 617-622
Risultati: 1-24 |